However, as the incidence of diabetes among transplant recipients medicated with tacrolimus is much higher than that in the general population, we had actually expected the influence of the investigated genetic variants on NODAT risk to be much more pronounced, as found by Yang et al. who observed an adjusted odds ratio value of ≥2 for SNPs within HNF4A and IRS1 genes among Hispanic American kidney transplant recipients [17]. This evidence concerns the gene HNF4A and diabetes mellitus.